Journal
BIOPOLYMERS
Volume 96, Issue 2, Pages 126-129Publisher
WILEY-BLACKWELL
DOI: 10.1002/bip.21443
Keywords
carbapenem resistant; intramuscular; peptide antibiotics; sepsis model; survival rate
Categories
Funding
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072219] Funding Source: NIH RePORTER
- NIAID NIH HHS [R01 AI072219] Funding Source: Medline
Ask authors/readers for more resources
Most antibacterial peptides exhibit low therapeutic indices in vivo. Peptide A3-APO was shown to exhibit high potency against Escherichia coli bacteremia when added intraperitoneally. To extend the studies to systemic infections against multidrug-resistant organisms, we studied the efficacy of A3-APO in mouse models of carbapenem-resistant Acinetobacter baumannii infection. When administered either intravenously at 2.5 mg/kg or intramuscularly (im) at 5 mg/kg twice or three times to mice infected with a carbapenem-resistant A. baumannii strain, peptide A3-APO reduced the bacterial counts by at least two log(10) units and increased the survival rate compared with untreated animals or mice treated with 40 mg/kg imipenem. Unlike after intraperitoneal or intravenous administration, A3-APO did not show toxic effects at 60 mg/kg dose im. (C) 2010 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 96: 126-129, 2011.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available